Experts say the emerging tech can dramatically accelerate advances in drug discovery, diagnostics and precision medicine.

Q4 2025 earnings call recap: 2026 revenue guidance, TearCare reimbursement milestone, OMNI growth outlook, margins and risks—read now.

Q4 2025 earnings call recap: 60% revenue growth, 2026 guidance of $60–$62M, PEDD/TriNav expansion, funding and risks—read now.

AICA currently supports auditing against 21 CFR Parts 11, 211, and 600, each mapped at the section and subsection levels.

The Triangle’s life sciences sector is in the midst of one of the most significant growth waves in its history. But as the ...

Every life sciences company knows that patient safety is non negotiable, but the way safety is managed—and the value ...

Caris Life Sciences Inc. CAI shares are up during Friday’s premarket session following better-than-expected fourth-quarter ...

Exact Sciences Corp. (NASDAQ:EXAS) is one of 15 stocks with the biggest hedge fund momentum, after gaining 31 hedge fund ...

Following a difficult start in 2025, the ever-evolving life sciences segment recovered strongly in the latter half of the ...

Upcycle, swap and style sustainably with the Natural Sciences Council! Bring a tee or tote to revamp and learn how small ...